MHMaike Vom Hove

Maike Vom Hove

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maike Vom Hove has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • C. Henn

    Universitätsklinik und Poliklinik für Kinder und Jugendliche Leipzig, Arbeitsgruppe päd. Pulmologie

    1 shared publication
  • Constance Henn

    Pediatricians Office Dr. Henn, Pediatric Pulmonology, 04177 Leipzig, Germany

    1 shared publication
  • Eva Robel-Tillig

    Pediatric Pneumology and Allergology, Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany

    1 shared publication
  • F. Prenzel

    Universitätsklinik und Poliklinik für Kinder und Jugendliche Leipzig, Arbeitsgruppe päd. Pulmologie

    1 shared publication
  • Freerk Prenzel

    Pediatric Pneumology and Allergology, Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany

    1 shared publication
  • Holm H. Uhlig

    Pediatric Pneumology and Allergology, Hospital for Children and Adolescents, University of Leipzig, Leipzig, Germany

    1 shared publication

Latest Publications

  • Open Access

    Identification and Characterization of a Rare Exon 22 Duplication in CFTR in Two Families

    by Simone Ahting, Constance Henn, Maike Vom Hove, Vincent Strehlow, Patricia Duffek, Sophie Behrendt, Stephan Drukewitz, Jasmin Berger, Simon Y. Graeber, Julia Hentschel

    Accurate genetic diagnosis is essential for appropriate treatment in cystic fibrosis (CF). Large copy number variants like duplications in the CFTR gene are rare and often classified as variants of uncertain significance (VUSs) due to unknown characteristics of the inserted material, complicating diagnosis and treatment decisions. We identified a previously uncharacterized exon 22 duplication (CFTRdup22) in the CFTR gene in two anamnestically unrelated people with CF, both exhibiting a mild phenotype. Initial classification as a VUS was based on standard genetic testing. We employed a custom next-generation sequencing (NGS) panel to determine the exact breakpoints of the duplication and conducted mRNA sequencing to confirm its effect on splicing. DNA and RNA analyses allowed for precise breakpoint determination, confirming that the duplication was in tandem and the reading frame remained intact. This, as well as a residual CFTRdup22 function of ~30% as measured via intestinal current measurement, is consistent with a clinically milder CF phenotype. Collectively, the precise characterization of the variants’ breakpoints, localization and orientation enabled us to reclassify the variant as likely pathogenic. This study highlights the importance of advanced genetic techniques, such as NGS and breakpoint analysis, in accurately identifying CF-causing variants. It underscores the importance of a comprehensive approach and persistence when suspecting a specific genetic condition. This can aid in reclassifying VUSs, providing a definitive diagnosis for the affected family and enabling appropriate therapeutic interventions, including the use of CFTR modulators.


  • Pulmonale Langzeitfolgen der bronchopulmonalen Dysplasie

    by C. Henn, J. Meir, U. Miehe, F. Prenzel, M. Vom Hove

    Zusammenfassung: Die bronchopulmonale Dysplasie (BPD) stellt eine der bedeutendsten Komplikationen der Frühgeburtlichkeit dar. Sie ist nach wie vor die häufigste chronische Lungenerkrankung im Kleinkindesalter. Frühgeborene mit BPD können bis ins Erwachsenenalter hinein unter pulmonalen Einschränkungen wie Atemwegsobstruktion und Überblähung sowie persistierenden respiratorischen Beschwerden leiden. Frühgeborene aus der Surfactant-Ära scheinen gleichermaßen von den Langzeitfolgen der BPD betroffen zu sein. Unklar ist, ob ein mögliches besseres Langzeitoutcome durch das Überleben von immer unreiferen Frühgeborenen verdeckt wird. Beim Management von Patienten mit chronischer Lungenerkrankung nach BPD sollte auf eine Abgrenzung zum Asthma bronchiale geachtet werden. Bisher konnte kein positiver Effekt einer Therapie mit inhalativen Steroiden beobachtet werden. Die Anwendung von inhalativen Bronchodilatatoren wird bisher nur bei Anzeichen einer reversiblen Atemwegsobstruktion oder Exazerbationen empfohlen.